WVP
HTGM

Worth Venture Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Worth Venture Partners’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,928
Closed -$776K – 165
2021
Q4 		$776K Hold
11,928
– – 0.38% 66
2021
Q3 		$817K Hold
11,928
– – 0.37% 72
2021
Q2 		$832K Buy
11,928
+7,366
+161% +$399K 0.31% 74
2021
Q1 		$299K Buy
+4,562
New +$346K 0.14% 86

Other funds holding HTGM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Worth Venture Partners's HTGM Position: Q1 2022 in Review

Worth Venture Partners sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2022, closing a stake of 11,928 shares — an estimated $776K sold.

Worth Venture Partners first reported a position in HTGM in Q1 2021 and held it in 4 quarters. The position peaked at $832K in Q2 2021. 21 funds tracked by Wall St. Rank hold HTGM as of Q1 2022.

  • Worth Venture Partners reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Worth Venture Partners sold 11,928 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2022, an estimated $776K.
  • Worth Venture Partners first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Worth Venture Partners's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $832K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2022.

Based on Worth Venture Partners's 13F filing for Q1 2022, filed 16 May 2022.